Healthcare -
Biotechnology - NASDAQ - US
$ 0.3171
-13.2 %
$ 39.5 M
Market Cap
-0.65
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Mersana Therapeutics, Inc.
| Revenue | 40.5 M |
| Cost Of Revenue | 1.63 M |
| Gross Profit | 38.9 M |
| Operating Expenses | 114 M |
| Operating Income | -73.3 M |
| Other Expenses | -4.14 M |
| Net Income | -69.2 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Revenue | 40.5 | 36.9 | 26.6 | 43 K | 0.8 | 42.1 | 10.6 | 17.5 | 25.2 | 10.4 |
| GROSS PROFIT | ||||||||||
| Cost Of Revenue | 1.6 | 148.3 | 0.9 | 132.0 | 67.0 | 55.0 | 59.9 | 0.9 | 32.0 | 21.4 |
| Gross Profit | 38.9 | (111.4) | 25.7 | (132.0) | (66.2) | (12.9) | (49.3) | 16.6 | (6.8) | (11.0) |
| OPERATING INCOME | ||||||||||
| Operating Expenses | 113.8 | 36.9 | 230.3 | 168.9 | 88.9 | 72.3 | 76.2 | 57.2 | 39.0 | 26.7 |
| Selling, General and Administrative Expenses | 40.8 | 59.5 | 57.0 | 36.9 | 21.9 | 17.3 | 16.3 | 10.5 | 7.0 | 5.3 |
| Research and Development Expenses | 73.0 | 148.3 | 173.4 | 132.0 | 67.0 | 55.0 | 59.9 | 46.7 | 32.0 | 21.4 |
| Operating Income | (73.3) | (171.0) | (204.7) | (169.7) | (87.7) | (29.2) | (65.7) | (39.6) | (13.8) | (16.3) |
| PRE-TAX INCOME | ||||||||||
| Interest Income Expense | 3.9 | 4.1 | 3.3 | 1.3 | 0.4 | 0.2 | 0 | 0 | 0 | 0 |
| Total Other Income | 4.6 | (0.7) | (0.4) | (1.2) | 65 K | 2.0 | 1.4 | 0.9 | 0.1 | 87 K |
| Pre-Tax Income | (68.8) | (171.7) | (204.2) | (170.1) | (88.0) | (28.2) | (64.3) | (38.7) | (13.7) | (16.4) |
| NET INCOME | ||||||||||
| Tax Provision | 0.4 | 0 | 3.3 | (0.9) | 0.4 | (1.0) | 1.4 | 0 | 0 | 2 K |
| Net Income | (69.2) | (171.7) | (207.5) | (169.2) | (88.4) | (27.2) | (64.3) | (38.7) | (13.7) | (16.4) |
| EPS | 0.56 | 1.48 | 2.22 | 2.4 | 1.44 | 0.63 | 2.79 | 3.22 | 0.78 | 0.94 |